Skip to main content
Contact Us
Subscribe
E-Edition
59°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kymera Therapeutics, Inc.
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
April 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
March 08, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
February 28, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
February 22, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
February 15, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
January 31, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 09, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
January 05, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Proposed Public Offering
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
January 04, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
January 02, 2024
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
December 13, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
December 10, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
December 07, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
November 13, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
November 02, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
November 01, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
October 27, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
October 26, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
October 16, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
September 18, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 28, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
August 03, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
July 27, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
June 22, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
June 09, 2023
From
Kymera Therapeutics, Inc.
Via
GlobeNewswire
Tickers
KYMR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.